Imugene Share Price Up on Agreement with Merck and Pfizer (ASX:IMU)
The Imugene [ASX:IMU] share price is up 6% following a supply agreement update. Imugene, the biotech stock, gained 600% over the last 12 months.

The Imugene [ASX:IMU] share price is up 6% following a supply agreement update. Imugene, the biotech stock, gained 600% over the last 12 months.

Up-and-coming biotech player Mesoblast [ASX:MSB] is on the up today. The regenerative medicine company announced some promising results from a Phase III drug trial from data that was shared at the American Heart Association’s annual ‘Scientific Sessions’, an exhibition of the latest findings and insights into all things heart health related.

It was an opinion piece discussing the recent listing (at the time) of Compass Pathways PLC [NASDAQ:CMPS]. A biotech stock with a very distinct twist…

‘Unprecedented change’ in the China infant formula market over the last 12 months led a2 Milk to alter its growth strategy, setting a medium-term goal of hitting NZ$2 billion in sales. a2 Milk Company [ASX:A2M] share price is currently trading for $6.09 a share, down 11%.

Tiny medtech stock Oneview Healthcare PLC [ASX:ONE] is on the up today. The ONE share price currently trading 6.98% higher at time of writing, paring back earlier gains of as much as 20.9% today.

The Creso Pharma [ASX:CPH] shares soared in early morning trade after the company announced its wholly-owned Canadian subsidiary, Mernova, secured over $800,000 in new purchase orders.
Investment ideas from the edge of the bell curve.
Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.
All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.
The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.
Fat Tail Daily is brought to you by the team at Fat Tail Investment Research
Copyright © 2026 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988